Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.

ABSTRACT:

Introduction

Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods

In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, and germline-controlled ctDNA levels were quantified and analyzed in patients with PDAC. Plasma samples (n = 1329) from 298 clinically validated patients were collected at diagnosis, perioperatively (MRD-window; within 2-12 weeks after surgery, before therapy), and during surveillance (>12 weeks post-surgery if no ACT or starting 4 weeks post-ACT) from November 2019 to March 2023.

Results

Of the initially diagnosed

SUBMITTER: Botta GP 

PROVIDER: S-EPMC11449101 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature